<div id="readability-page-1">Virax Biolabs Group Ltd ( VRAX ) shares declined 12.79% to $0.60 in after-hours trading on Wednesday. Check out the current price of VRAX stock here. According to Benzinga Pro data, the stock closed on Wednesday at $0.69, up 75.11%. <h2>$5 Million Private Placement Details</h2> The London-based biotechnology company announced definitive agreements to sell 12.5 million ordinary shares at $0.40 per share in a private placement. H.C. Wainwright &amp; Co. is serving as the exclusive placement agent. Gross proceeds are expected to total $5 million before fees and expenses. See Also: Why Did KALA BIO Shares Jump Over 22% After Hours? <h2>Warrant Terms And Modifications</h2> The offering includes preferred investment options priced at $0.40 per share, exercisable immediately for five years. The company will also reduce the exercise prices on its 2023 Series A and Series B preferred investment options to $0.40 to match the new offering and extend their expiration to five years from the Initial Registration Statement's effective date. <h2>Expected Closing And Use Of Proceeds</h2> The transaction is expected to close on or about Thursday, subject to customary conditions. Virax intends to use net proceeds for working capital and general corporate purposes. The securities have not been registered under the Securities Act of 1933 and are being sold in a transaction not involving a public offering. <h2>Stock Performance</h2> VRAX is down 68.87% so far this year. Virax Biolabs ( VRAX ) has a market capitalization of $3.01 million and a 52-week range of $0.35 to $3.20. Benzinga Edge Stock Rankings indicate that VRAX stock has a negative price trend across all time frames. Look at other players in this segment. &lt;figure class=&#34;wp-block-image aligncenter size-full&#34;&gt;<img width="429" height="270" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/04021011/image-61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/04021011/image-61.png"/>&lt;/figure&gt; Read Next: <ul> <li>What Sparked Polyrizon’s (PLRZ) 140% After-Hours Stock Surge?</li> </ul> Photo Courtesy: PeopleImages on Shutterstock.com Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</div>

VRAX

Virax Biolabs (VRAX) 的股價在盤後下跌了 12.79%，至 0.60 美元，此前股價上漲了 75.11%，達到 0.69 美元。該公司宣佈進行 500 萬美元的私募配售，出售 1250 萬股，每股價格為 0.40 美元，H.C. Wainwright & Co. 擔任配售代理。此次發行包括優先投資選項和降低的 A 類和 B 類期權行使價格。所得款項將用於營運資金和公司用途。VRAX 的股票今年下跌了 68.87%，市值為 301 萬美元

Virax Biolabs (VRAX) 的股票在盤後交易中降温，此前曾上漲 75%